X4 Pharmaceuticals, Inc. (XFOR): Price and Financial Metrics
XFOR Stock Summary
- X4 Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 10.4% of US listed stocks.
- X4 Pharmaceuticals Inc's stock had its IPO on November 16, 2017, making it an older stock than just 10.54% of US equities in our set.
- XFOR's price/sales ratio is 52.27; that's higher than the P/S ratio of 94.44% of US stocks.
- If you're looking for stocks that are quantitatively similar to X4 Pharmaceuticals Inc, a group of peers worth examining would be MRUS, GSIT, LOGC, LPTX, and OVID.
- XFOR's SEC filings can be seen here. And to visit X4 Pharmaceuticals Inc's official web site, go to www.x4pharma.com.
XFOR Stock Price Chart Interactive Chart >
XFOR Price/Volume Stats
| Current price | $9.02 | 52-week high | $11.11 |
| Prev. close | $9.45 | 52-week low | $5.38 |
| Day low | $8.89 | Volume | 75,000 |
| Day high | $9.44 | Avg. volume | 112,648 |
| 50-day MA | $9.10 | Dividend yield | N/A |
| 200-day MA | $7.83 | Market Cap | 156.80M |
X4 Pharmaceuticals, Inc. (XFOR) Company Bio
X4 Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The Company specializes in developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases including primary immunodeficiencies and cancer. X4's oral small molecule drug candidates antagonize the CXCR4 pathway which plays a central role in immune surveillance.
Latest XFOR News From Around the Web
Below are the latest news stories about X4 Pharmaceuticals Inc that investors may wish to consider to help them evaluate XFOR as an investment opportunity.
X4 Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare ConferenceBOSTON, April 07, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021. Details are as follows:Conference: 20th Annual Needham Virtual Healthcare Conference Date: Monday, April 12, 2021Time: 2:15 PM ETPresentation Webcast Link A live webcast of the presentation from the Needham Virtual Healthcare Conference will be available on the investors section of the X4 Pharmaceuticals’ website at www.x4pharma.com. After the live webcast, the event will remain archived on the X4 Pharmaceuticals’ website for appr... |
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, April 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that, on March 31, 2021, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 58,000 shares of X4’s common stock and were granted as an inducement material to the new employees entering into employment with X4 in acco... |
The X4 Pharmaceuticals (NASDAQ:XFOR) Share Price Is Up 47% And Shareholders Are Holding OnThere's no doubt that investing in the stock market is a truly brilliant way to build wealth. But if when you choose to... |
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update2021 expected to be a year of key value-driving catalysts as company advances multiple clinical programs with lead candidate mavorixafor Company anticipates completing full enrollment in WHIM Phase 3 trial in 2021 and presenting clinical data from the ongoing Phase 1b Waldenström’s trial throughout the year Conference call today at 8:30 a.m. ET BOSTON, March 04, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today reported financial results for the fourth quarter and full year ended December 31, 2020. The company also provided an update on its lead product candidate, mavorixafor, a novel small molecule currently being evaluated in a Phase 3 ... |
X4 Pharmaceuticals, Inc. to Host Earnings CallNEW YORK, NY / ACCESSWIRE / March 4, 2021 / X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 4, 2021 at 8:30 AM Eastern Time. |
XFOR Price Returns
| 1-mo | -5.55% |
| 3-mo | 14.32% |
| 6-mo | 33.43% |
| 1-year | N/A |
| 3-year | -92.58% |
| 5-year | N/A |
| YTD | 40.28% |
| 2020 | -39.91% |
| 2019 | -23.13% |
| 2018 | -81.82% |
| 2017 | N/A |
| 2016 | N/A |
Continue Researching XFOR
Want to see what other sources are saying about X4 Pharmaceuticals Inc's financials and stock price? Try the links below:X4 Pharmaceuticals Inc (XFOR) Stock Price | Nasdaq
X4 Pharmaceuticals Inc (XFOR) Stock Quote, History and News - Yahoo Finance
X4 Pharmaceuticals Inc (XFOR) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...